BBS-Bioactive Bone Substitutes
0.463 EUR -1.28%3,866 investors are following this company
BBS-Bioactive Bone Substitutes is a medical technology company. The company designs, develops and constructs biological implants for patients with bone defects and healing problems. The company's solutions are resold under the Artebone brand and are based on tricalcium phosphate (TCP) and bone protein, which stimulates the bone healing process. The company was founded in 2003 and is headquartered in Oulu.
P/E (24e)
-2.17
EV/EBIT (adj.) (24e)
-4.09
P/B (24e)
9.19
Dividend yield-% (24e)
-
Target price
0.50 EUR
Recommendation
Reduce
Updated
27.2.2024
First North Finland
BONEH
Daily low / high price
0.456 / 0.466
EUR
Market cap
9.4M EUR
Turnover
9.54K EUR
Volume
21K
Risk and recommendation
HighRiskLow
SellRecommendationBuy
Analyst
Antti Siltanen
Analyst
Latest videos
Financial calendar
General meeting
28.05.2024
Interim report
30.08.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Reisjärven Kunta | 13.9 % | 13.9 % |
Finha Capital | 12.1 % | 12.2 % |
Premium
This content is for our Premium customers only.
Insider Transactions
Insider | Date | Total value |
---|---|---|
Juliusz Rakowski | 18.12.2023 | 10,000EUR |
Jarmo Halonen | 18.12.2023 | 2,560EUR |
Premium
This content is for our Premium customers only.
Income statement
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 1.2 | 2.8 | 6.7 |
growth-% | 4,499.5 % | 537.6 % | 138.6 % | 139.3 % | ||||
EBITDA | -2.4 | -2.3 | -2.7 | -3.1 | -3.8 | -3.5 | -3.0 | -2.1 |
EBIT (adj.) | -2.6 | -2.6 | -3.0 | -3.4 | -4.0 | -4.0 | -3.6 | -2.7 |
EBIT | -2.6 | -2.6 | -3.0 | -3.4 | -4.0 | -4.0 | -3.6 | -2.7 |
Profit before taxes | -2.7 | -2.8 | -3.1 | -3.5 | -4.1 | -4.3 | -3.9 | -2.9 |
Net income | -2.7 | -2.8 | -3.1 | -3.5 | -4.1 | -4.3 | -3.9 | -2.9 |
EPS (adj.) | -0.42 | -0.40 | -0.32 | -0.18 | -0.21 | -0.22 | -0.20 | -0.15 |
growth-% | ||||||||
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dividend ratio |
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | -60,775.0 % | -58,500.0 % | -68,150.0 % | -78,738.0 % | -2,088.3 % | -300.4 % | -108.9 % | -30.8 % |
EBIT-% (adj.) | -66,125.0 % | -64,275.0 % | -73,775.0 % | -84,150.0 % | -2,197.0 % | -343.2 % | -128.9 % | -40.0 % |
EBIT-% | -66,125.0 % | -64,275.0 % | -73,775.0 % | -84,150.0 % | -2,197.0 % | -343.2 % | -128.9 % | -40.0 % |
ROE | -59.6 % | -57.0 % | -78.2 % | -74.2 % | -135.9 % | 368.8 % | 73.9 % | 34.1 % |
ROI | -24.4 % | -23.1 % | -28.5 % | -31.6 % | -42.0 % | -44.6 % | -36.5 % | -24.2 % |
Valuation
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Share price (EUR) | 3.90 | 1.79 | 1.05 | 0.49 | 0.46 | 0.46 | 0.46 | 0.46 |
Shares | 6.6 | 7.0 | 9.7 | 19.3 | 19.4 | 19.4 | 19.4 | 19.4 |
Market cap | 25.6 | 12.5 | 10.1 | 9.4 | 9.0 | 9.0 | 9.0 | 9.0 |
Enterprise value | 28.4 | 17.7 | 15.0 | 13.0 | 16.5 | 21.5 | 26.2 | 30.4 |
EV/S | 7,095.0 | 4,417.5 | 3,758.6 | 3,242.8 | 89.8 | 18.4 | 9.4 | 4.5 |
EV/EBITDA | - | - | - | - | - | - | - | - |
EV/EBIT (adj.) | - | - | - | - | - | - | - | - |
EV/EBIT | - | - | - | - | - | - | - | - |
P/E (adj.) | - | - | - | - | - | - | - | - |
P/E | - | - | - | - | - | - | - | - |
P/B | 4.2 | 3.4 | 2.4 | 1.8 | 9.2 | - | - | - |
P/S | 6,407.2 | 3,131.2 | 2,533.8 | 2,359.1 | 48.8 | 7.6 | 3.2 | 1.3 |
Dividend yield | ||||||||
Equity ratio | 48.0 % | 34.6 % | 40.0 % | 48.2 % | 11.3 % | -34.8 % | -69.3 % | -85.5 % |
Gearing ratio | 45.2 % | 141.6 % | 114.7 % | 69.1 % | 773.7 % | -381.9 % | -241.2 % | -213.0 % |
Quarter data
Q1/23 | Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24e | Q2/24e | Q3/24e | Q4/24e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.2 | ||||||
EBITDA | -1.5 | -1.7 | -3.1 | -1.9 | -2.0 | ||||
EBIT | -1.6 | -1.8 | -3.4 | -2.0 | -2.1 | ||||
Profit before taxes | -1.6 | -1.8 | -3.5 | -2.0 | -2.1 | ||||
Net income | -1.6 | -1.8 | -3.5 | -2.0 | -2.1 |
ShowingAll content types
BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd
BBS-Bioactive Bone Substitutes Plc: Annual General Meeting in 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools